Table 1. Characteristics of the studies included in the systematic analysis.
| Author (Year) | SD | TR | NPIP | IT | QES | PEG | PCG |
|---|---|---|---|---|---|---|---|
| RAL group | |||||||
| Lennox JL, 2009 | RCT | RAL | 282 | 96 weeks | High | 282 | 284 |
| Jeffrey L Lennox, 2010 | RCT | RAL | 281 | 96 weeks | High | 281 | 282 |
| Pedro Cahn, 2013 | RCT | RAL | 362 | 48 weeks | High | 361 | 354 |
| Francois Raffi, 2014 | RCT | RAL | 77 | 96 weeks | High | 401 | 404 |
| Francois Raffi, 2013 (1) | RCT | RAL | 411 | 96 weeks | High | 411 | 411 |
| Joseph J Eron, 2013 | RCT | RAL | 462 | 240 weeks | High | 462 | 237 |
| Joseph J Eron Jr, 2011(1) | RCT | RAL | 382 | 48 weeks | High | 386 | 389 |
| Joseph J Eron Jr, 2011(2) | RCT | RAL | 388 | 48 weeks | High | 389 | 386 |
| Joseph J Eron, 2010 (1) | RCT | RAL, | 174 | 24 weeks | High | 177 | 175 |
| Joseph J Eron, 2010 (2) | RCT | RAL | 176 | 24 weeks | High | 176 | 178 |
| Jean-Michel Molina, 2012 | RCT | RAL | 351 | 96 weeks | High | 361 | 363 |
| Beatriz Grinsztejn, 2007 (1) | RCT | RAL | 44 | 24 weeks | High | 44 | 45 |
| Beatriz Grinsztejn, 2007 (2) | RCT | RAL | 45 | 24 weeks | High | 45 | 45 |
| Beatriz Grinsztejn, 2007 (3) | RCT | RAL | 45 | 24 weeks | High | 45 | 45 |
| Jurgen K. Rockstroh, 2011 (1) | RCT | RAL | 219 | 96 weeks | High | 219 | 230 |
| Jurgen K. Rockstroh, 2011 (2) | RCT | RAL | 59 | 96 weeks | High | 59 | 47 |
| Jurgen K. Rockstroh, 2011 (3) | RCT | RAL | 416 | 96 weeks | High | 416 | 219 |
| Jurgen K. Rockstroh, 2011 (4) | RCT | RAL | 39 | 96 weeks | High | 39 | 15 |
| Jurgen K. Rockstroh, 2013 | RCT | RAL | 282 | 48 weeks | High | 282 | 284 |
| Y. Yazdanpanah, 2009 | RCT | RAL | 100 | 48 weeks | High | 100 | 100 |
| Babafemi Taiwo, 2011 | RCT | RAL | 112 | 48 weeks | High | 112 | 112 |
| Roy T. Steigbigel, 2008 (1) | RCT | RAL | 232 | 48 weeks | High | 232 | 118 |
| Roy T. Steigbigel, 2008 (2) | RCT | RAL | 230 | 48 weeks | High | 230 | 119 |
| Joseph J Eron, 2013 | RCT | RAL | 462 | 240 weeks | Medium | 462 | 237 |
| Slim Fourati1, 2015 | RCT | RAL | 306 | 48 weeks | High | 306 | 306 |
| Richard Elion, MD, 2013 | RCT | RAL | 351 | 48 weeks | High | 351 | 351 |
| Amedeo Capetti, 2013 | OBS | RAL | 258 | 206 weeks | Medium | 258 | |
| Jintanat Ananworanich, 2012 | OBS | RAL | 19 | 119 days | High | 19 | |
| Daniele Armenia, 2012 | OBS | RAL | 23 | 24 weeks | High | 23 | |
| Pascal Obong Bessong, 2013 | OBS | RAL | 127 | 24 weeks | High | 127 | |
| Vero´nica Briz, 2011 | RT | RAL | 19 | 80.1weeks | High | 19 | |
| EVG group | |||||||
| Calvin Cohen, 2011 | RCT | EVG | 50 | 48 weeks | High | 50 | 25 |
| Andrew R. Zolopa, 2010 (1) | RCT | EVG | 75 | 48 weeks | High | 75 | 73 |
| Andrew R. Zolopa, 2010 (2) | RCT | EVG | 75 | 48 weeks | High | 75 | 73 |
| Andrew R. Zolopa, 2010 (3) | RCT | EVG | 74 | 48 weeks | High | 74 | 73 |
| Paul E Sax, 2012 | RCT | EVG | 348 | 48 weeks | High | 348 | 352 |
| Jean-Michel Molina, 2012 | RCT | EVG | 361 | 96 weeks | High | 361 | 351 |
| Jose R Arribas, 2014 | RCT | EVG | 293 | 96 weeks | High | 293 | 145 |
| Slim Fourati1, 2015 | RCT | EVG | 306 | 48 weeks | High | 306 | 306 |
| Richard Elion, MD, 2013 | RCT | EVG | 351 | 48 weeks | High | 351 | 351 |
| DTG group | |||||||
| Antonella Castagna, 2014 | RCT | DTG | 183 | 24 weeks | High | 183 | 183 |
| Francois Raffi, 2013 (1) | RCT | DTG | 411 | 96 weeks | High | 411 | 411 |
| Pedro Cahn, 2013 | RCT | DTG | 357 | 48 weeks | High | 361 | 354 |
| Francois Raffi, 2013 (2) | RCT | DTG | 411 | 96 weeks | High | 411 | 411 |
| Joseph J. Eron, 2012 (1) | RCT | DTG | 27 | 24 weeks | High | 27 | 24 |
| Joseph J. Eron, 2012 (2) | RCT | DTG | 24 | 24 weeks | High | 24 | 27 |
SD, study design; TR, treatment regimen; NPIP, No. of patients in the ITT population; IT, intervention time; QES, quality evaluation of the study; PEG, patients in the experimental group; PCG, patients in the control group; RT, retrospective study. “n” indicates the number of trials in the same literature. “OBS” indicates an observational study. “[n, n%]” indicates the number of patients and their proportion.